Zydus and Lupin join hands to Co-market treatment

Zydus Lifesciences Limited and Lupin Limited have entered a licensing and supply agreement to co-market Saroglitazar Mg, designed for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. Saroglitazar Mg offers enhanced compliance with its once daily 4mg dose, reducing pill burden and providing patients with greater convenience.

Under the agreement, Lupin gains semi-exclusive rights to co-market the product in India under the brand name LINVAS. Zydus will continue marketing the drug under the brand names Lipaglyn and Bilypsa. Lupin will make upfront licensing fees and milestone payments to Zydus based on predefined achievements.

In India, NAFLD is not confined to obese or Diabetes Mellitus patients; it can also develop independently of obesity, termed "lean" NAFLD. The prevalence of NAFLD/NASH has risen due to increased obesity and other lifestyle-related conditions.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., noted that Saroglitazar Mg has substantially improved patients' quality of life. Nilesh Gupta, Managing Director of Lupin, expressed excitement about the partnership, stating it reinforces their commitment to meeting patients' unmet needs in India and enhancing their gastroenterology portfolio.